Related Experiment Video
Updated: Apr 15, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.9K
High-risk nonmuscle invasive bladder cancer
Anna Orsola1, Joan Palou2, Eduardo Solsona3
1Bladder Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA.
Hematology/Oncology Clinics of North America
|April 4, 2015
Summary
The risk of progression for high-grade T1 (HGT1) cancer is 21%, based on recent meta-analysis data. This finding offers improved outcomes compared to historical expectations for HGT1 cancer.
Area of Science:
- Oncology
- Cancer Research
- Uro-oncology
Background:
- High-grade T1 (HGT1) bladder cancer requires accurate risk assessment for progression.
- Historical data suggested a 'rule of thirds' for HGT1 outcomes.
- Recent evidence necessitates an update on HGT1 cancer progression risk.
Purpose of the Study:
- To establish the current risk of progression for high-grade T1 (HGT1) bladder cancer.
- To compare recent findings with historical expectations for HGT1 outcomes.
Main Methods:
- A meta-analysis of large series was conducted.
- Updated information was utilized to assess progression risk.
- Retrospective observational studies were the primary data source.
Main Results:
- The established risk of progression for HGT1 cancer is 21%.
- These outcomes are more favorable than those predicted by the traditional 'rule of thirds'.
- The study acknowledges limitations inherent in retrospective observational data.
Conclusions:
- The updated progression risk for HGT1 cancer is 21%.
- This indicates a better prognosis than previously assumed.
- Caution is advised due to potential biases in retrospective studies.
